Janine Simons, SABCS 2020 – Radioactive Iodine Seed Localisation in the Axilla with the Sentinel Node Procedure: The RISAS Trial
We had the pleasure to talk to Janine Simons (Erasmus University Medical Center, Rotterdam, Netherlands) about the RISAS study and its findings (Clinical Trial Identifier: NCT02800317). The abstract ‘Radioactive Iodine Seed placement in the Axilla with Sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer: Results of the prospective multicenter RISAS trial‘ (ABSTRACT NUMBER: GS1-10) was presented at the virtual SABCS 2020, 8-11 December 2020.
- Could you tell us a little about radioactive iodine seed localisation and the history of its use to date in breast cancer therapy?
- What was the rationale for combining radioactive iodine seed localisation in the axilla with the sentinel node procedure (RISAS) for cancer staging after neoadjuvant chemotherapy?
- Could you give us an overview of the RISAS study and its findings?
- What are the implications of these findings for clinical practice?
- How do you expect the use of radioactive seed localisation to develop in the future?
Speaker Disclosures: Dr Janine Simons has nothing to disclose in relation to this video interview. Dr Janine Simons was previously at the Department of Surgery, Maastricht University Medical Center, Maastricht, The Netherlands, where the RISAS study was conducted.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of the San Antonio Breast Cancer Symposium (SABCS) 2020.
Share this Video
Related Videos In Breast Cancer
Sara Hurvitz, SABCS 2022: Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2+ metastatic breast cancer: DESTINY-Breast03
Trastuzumab deruxtecan (T-DXd) is approved in the United States and European Union for use in patients with HER2+ unresectable/metastatic breast cancer. Approval was based on the randomized, multicenter, open-label, phase III DESTINY-Breast03 (NCT03529110) trial. In this interview we discuss with Dr Sara Hurvitz (David Geffen School of Medicine, UCLA Los Angeles, CA, USA) updated data […]
Erika Hamilton, SABCS 2022: Trastuzumab deruxtecan and pertuzumab in HER2+ metastatic breast cancer
Preclinical findings have suggested that when used in combination with anticancer treatments, trastuzumab deruxtecan (T-Dxd) could improve treatment efficacy in HER2+ metastatic breast cancer (mBC). In this interview we discuss with Dr Erika Hamilton (Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN) preliminary data from the dose expansion phase of the DESTINY-Breast07 (DB-07) (NCT04538742) trial. […]
Sudeep Gupta, SABCS 2022: Addition of platinum to neoadjuvant chemotherapy in patients with triple-negative breast cancer: A phase III randomized controlled trial
The impact of adding platinum on long-term outcomes in triple-negative breast cancer (TNBC) has not been definitively established. The controlled, single-centre, phase III study conducted by Tata Memorial Hospital in Mumbai, India evaluated the efficacy and toxicity of adding platinum to standard neoadjuvant chemotherapy in patients with triple-negative breast cancer. In this touchONCOLOGY interview, we speak […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!